On the other hand, GFAP is known as a cytoskeletal component of astrocytes,13 and astrocyte activation has been implicated as a potential driver or effect of pathological changes of both AD and non‐AD, because clinical studies showed that patients with non‐AD, such as dementia with Lewy bodies and frontotemporal degeneration, also had higher CSF, plasma, and serum GFAP levels than those with normal cognition.4, 42. This evidence concerns the gene GFAP and Alzheimer disease.